StackItSmart

Compound reference

CJC-1295 (no DAC)

Mod GRF 1-29

Peptides1 cited findingClinical review: not reviewed

Identity & applicability

Regulatory recordSupporting passage inspected

FDA evaluates CJC-1295 without DAC and CJC-1295 with DAC as different active moieties. Salt and DAC identity must be specified before applying study findings; a half-life for a long-acting DAC preparation should not be attached to non-DAC products.[1]

  • Names used by vendors do not establish that a vial matches a studied formulation.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Fresh scoped source inspection; locator/date corrections and original full-text evidence recorded. Independent editorial review pending; no qualified clinical review.

· Independent editorial worker reopened the cited support; coordinator resolved the requested bibliography corrections and integrated the bounded claim. Original and corrected cell figures remain scientifically inconsistent as stated. No qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Used FDA’s active-moiety distinctions; withheld a non-DAC half-life inferred from the DAC trial.

  • Direct non-DAC pharmacokinetic and clinical outcome sources remain necessary.
  • Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. FDA December 2024 compounding briefing: CJC-1295-related bulk substances

    US Food and Drug Administration. 2024-11-15. Regulatory document.

    Inspected location: PDF p. 10/printed p. 6: two active moieties/five BDSs; PDF pp. 32-35/printed pp. 28-31: toxicity and identity qualification; PDF pp. 40-42/printed pp. 36-38: safety/cohort overlap; PDF p. 50/printed p. 46: effectiveness

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • peptide-fda-cjc-2024: Identity and active-moiety distinctions, pp. 7–8

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.